Expression of platelet-derived growth factor and its receptors in spontaneous canine hemangiosarcoma and cutaneous hemangioma
Expression of platelet-derived growth factor and its receptors in spontaneous canine hemangiosarcoma and cutaneous hemangioma
复制标题
DOI：
10.14670/hh-27.601
复制
发表时间：
2012-05-01
影响因子：
2
通讯作者：
Sakai, H.
中科院分区：
文献类型：
--
作者：
Abou Asa, S.;Murai, A.;Sakai, H.
血管肉瘤（HSA）是血管内皮细胞（EC）的恶性肿瘤。我们之前关于犬 HSA 中血管内皮生长因子、碱性成纤维细胞生长因子及其受体表达的报告表明肿瘤生长的自分泌/旁分泌机制。然而，其他血管生成生长因子对犬 HSA 的影响尚未阐明。因此，通过免疫组织化学分析研究血小板源性生长因子（PDGF）及其受体的表达。对 46 个犬 HSA 和 21 个犬皮肤血管瘤 (HA) 进行了分析。对于免疫组织化学，使用抗 PDGF-BB、抗 PDGFR-α 和抗 PDGFR-β 抗体作为一抗。免疫反应性分为强阳性（>25%阳性肿瘤细胞）、弱阳性（1-25%阳性肿瘤细胞）和阴性（如果根本不染色）。在皮肤HA中，分别有33.3%和57.1%的病例呈强阳性和弱阳性，并且分别有43.5%和13.0%的HSA呈PDGF-BB强阳性和弱阳性。此外，PDGFR-α 分别有 38.1% 和 28.6% 的皮肤 HA 病例呈强阳性和弱阳性，23.9% 和 4.3% 的 HSA 病例分别呈强阳性和弱阳性。 35 例 HSA 病例 (76.1%) 呈强阳性，其余 11 例 (23.9%) 呈 PDGFR-β 弱阳性。相比之下，PDGFR-β 的 18 例（72.0%）皮肤 HA 呈阴性，只有 3 例（12.0%）呈弱阳性。 PDGFR-β HSA 强阳性病例比例显着高于皮肤 HA（P
Hemangiosarcoma (HSA) is a malignant neoplasia of vascular endothelial cells (ECs). Our previous report on the expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors in canine HSA suggested an autocrine/paracrine mechanism of tumor growth. However, the influence of other angiogenic growth factors in canine HSA was not elucidated; therefore, the expression of platelet-derived growth factor (PDGF) and its receptors was investigated by immunohistochemical analysis. Forty-six canine HSAs and 21 canine cutaneous hemangiomas (HAs) were analyzed. For immunohistochemistry, anti-PDGF-BB, anti-PDGFR-alpha, and anti-PDGFR-beta antibodies were utilized as primary antibodies. Immunoreactivities were scored as strongly positive (>25% positive neoplastic cells), weakly positive (1-25% positive neoplastic cells), and negative if not staining at all. In cutaneous HA, 33.3% and 57.1% of cases were strongly and weakly positive, respectively, and 43.5% and 13.0% of HSAs were strongly and weakly positive for PDGF-BB, respectively. Moreover, 38.1% and 28.6% of cutaneous HAs cases were strongly and weakly positive, respectively, and 23.9% and 4.3% of HSAs cases were strongly and weakly positive, respectively, for PDGFR-alpha. Thirty-five HSAs cases (76.1%) were strongly positive, and the remaining 11 (23.9%) were weakly positive for PDGFR-beta. In contrast, 18 (72.0%) cutaneous HAs were negative, and only 3 cases (12.0%) were weakly positive, for PDGFR-beta. The proportion of strongly positive cases of HSAs was significantly higher than that of cutaneous HA for PDGFR-beta (P